Abstract

Although detailed pharmacokinetic studies have been performed on most major anticancer drugs currently in use, assays of drug concentration in plasma, cerebrospinal fluid and uring have not been routinely employed to determine variations in bioavailability and to adjust dosing accordingly. We wish through this grant to supply such data to supplement protocol drug trials conducted by the CALGB. Cytarabine levels achieved by several dosages and schedules of administration are currently being assayed. It is planned to follow this with drug level studies of platinum analogs, methotexate, adriamycin and vinca (Catharanthus) alkaloids to determine inter- and intrapatient variability, variations due to route or schedule, and their relationship of bioavailability to toxicity and to therapeutic benefit. These studies will use existing expertise and facilities within CALGB supported in sequence on priorities determined by the Chemotherapy Committee of CALGB.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
7U10CA044691-01
Application #
3558540
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1986-04-01
Project End
1988-03-31
Budget Start
1986-04-01
Budget End
1987-03-31
Support Year
1
Fiscal Year
1986
Total Cost
Indirect Cost

  Institution

Name
University of Maryland Baltimore
Department
Type
Schools of Medicine
DUNS #
003255213
City
Baltimore
State
MD
Country
United States
Zip Code
21201

  Publications

Lewis, Lionel D; Miller, Antonius A; Owzar, Kouros et al. (2013) The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics 23:29-33
Lewis, Lionel D; Miller, Antonius A; Rosner, Gary L et al. (2007) A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res 13:3302-11
Klein, Cheri E; Kastrissios, Helen; Miller, Antonius A et al. (2006) Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol 57:199-206
Miller, Antonius A; Rosner, Gary L; Egorin, Merrill J et al. (2004) Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin Cancer Res 10:8325-31
Akerley, Wallace; Herndon, James E; Egorin, Merrill J et al. (2003) Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer 97:2480-6
Rosner, Gary L; Stadler, Walter; Ratain, Mark J (2002) Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 20:4478-84
Fleming, Gini F; Meropol, Neal J; Rosner, Gary L et al. (2002) A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res 8:3718-27
Jodrell, D I; Murray, L S; Hawtof, J et al. (1996) A comparison of methods for limited-sampling strategy design using data from a phase I trial of the anthrapyrazole DuP-941. Cancer Chemother Pharmacol 37:356-62
Kearns, C M; Gianni, L; Egorin, M J (1995) Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 22:16-23
Ratain, M J; Rosner, G; Allen, S L et al. (1995) Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J Clin Oncol 13:741-7

Showing the most recent 10 out of 20 publications